Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Roflumilast (PDE4 Inhibitor)
Treatment for COPD
Typical Dosage: Roflumilast 500 mcg once daily
Effectiveness
60%
Safety Score
55%
Clinical Trials
4
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
55
DangerousModerateSafe
Treatment Details
Dosage Range
Roflumilast 500 mcg once daily
Time to Effect
Weeks-months (exacerbation reduction)
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
10(Treat 10 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
7(Treat 7 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$5,400
Monitoring:$800
Side Effect Mgmt:$100
Total Annual:$6,300
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$200,000/QALY
QALYs Gained
0.02
Outcome-Based Costs
Cost per Responder
$12,600
Comparison vs Usual Care
Cost Difference
+$6,300/year
More expensive
QALY Difference
+0.02 QALYs
Better outcomes
Dominance
No dominance
Roflumilast (PDE4 Inhibitor) Outcomes
for COPD
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+50%
Common Side Effects
Diarrhea
+15%
Nausea
+8%
Headache
+7%
Weight loss
+5%
Insomnia
+4%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
3 completed trials for Roflumilast (PDE4 Inhibitor) in COPD
Effects of Roflumilast in Hospitalized Chronic Obstructive Pulmonary Disease( COPD) on Mortality and Re-hospitalization
NCT01973998COMPLETEDPHASE3
68 participants
INTERVENTIONAL
Philadelphia, United States
Started: Nov 1, 2013
Efficacy and Safety of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-06)
NCT00242294COMPLETEDPHASE2, PHASE3
570 participants
INTERVENTIONAL
Osaka, Japan
Started: Nov 1, 2004
Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients Older Than 40 Years With Chronic Obstructive Pulmonary Disease (APTA-2217-08)
NCT00246935COMPLETEDPHASE3
150 participants
INTERVENTIONAL
Osaka, Japan
Started: May 1, 2005